CAL-101 CAS: 870281-82-6
MF: C22H18FN7O
MW: 415.42
A potent PI3K p110δ inhibitor.

CAL-101 (CAS 870281-82-6)

CAL-101 | CAS 870281-82-6 is rated 5.0 out of 5 by 1.
  • y_2020, m_11, d_22, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364453, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 88ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Idelalisib; GS-1101
Application: CAL-101 is a potent PI3K p110δ inhibitor
CAS Number: 870281-82-6
Purity: ≥98%
Molecular Weight: 415.42
Molecular Formula: C22H18FN7O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

CAL-101is a potent and selective PI3K p110δ inhibitor with an IC50 of 2.5 nM. This compound induces selective cytotoxicity in CLL cells and is independent of IgVH mutational status. CAL--101 also acts as an antagonist in CD40L-mediated CLL cell survival.


References

1. Herman, S.E. et al. 2010. Blood. 116(12): 2078-2088. PMID: 20522708
2. Lannutti, B.J. et al. 2011. Blood. 117(2): 591-594. PMID: 20959606
3. Meadows, S.A. et al. 2012. Blood. 119(8): 1897-1900. PMID: 22210877
4. Xu, H. et al. 2013. Nature. 496(7446): 523-527. PMID: 23619696
5. Chiron, D. et al. 2014. Cancer Discov. 4(9): 1022-1035. PMID: 25082755
6. Boucrot, E. et al. 2015. Nature. 517(7535): 460-465. PMID: 25517094
7. Mounayar, M. et al. 2015. Stem Cells. 33(6): 1892-1901. PMID: 25753288

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in water (<1 mg/ml at 25 °C), DMSO (83 mg/ml at 25 °C), ethanol (35 mg/ml at 25 °C), and 30% PEG400/0.5% Tween80/5% propylene glycol (30 mg/ml at 25 °C).
Storage :
Store at -20° C
Melting Point :
296.57° C (Predicted)
Boiling Point :
~599.1° C at 760 mmHg (Predicted)
Density :
~1.5 g/cm3 (Predicted)
pK Values :
pKb: 6.23 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
11625818
SMILES :
CC[[email protected]@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

CAL-101 (CAS 870281-82-6)  Product Citations

See how others have used CAL-101 (CAS 870281-82-6). Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 25523586  2015. MAbs. 7: 192-8.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 135ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Fiorcari Fiorcari, S. et al. (PubMed 24376763) reported that the PI3-kinase delta inhibitor Idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. -SCBT Publication Review
Date published: 2015-02-21
  • y_2020, m_11, d_22, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364453, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 11ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.